Anzeige
Mehr »
Login
Mittwoch, 22.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Kursexplosion von 383 % seit November und massiver Solana-Outperformer!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
315 Leser
Artikel bewerten:
(1)

Acclime establishes a strong foothold in Australia with the acquisition of CoSec Corporate Services

Finanznachrichten News

HONG KONG, March 1, 2021 /PRNewswire/ -- Acclime, the premier corporate services provider in Asia, is pleased to announce that it has completed the acquisition of CoSec Corporate Services, a highly regarded firm specialising in assisting foreign clients enter and operate in Australia. With this acquisition, in addition to the presence in nine key Asian jurisdictions and a European sales office in the Netherlands, Acclime's footprint now extends into Australia, with additional sales offices in the United States of America and the United Kingdom.

Acclime Logo

Founded by Blair Lucas and Paul Dixon in 2011, CoSec offers clients entering and operating in Australia a full suite of incorporation, hosting and compliance services under one roof. The firm has extensive experience in assisting life science companies looking to conduct clinical trials in Australia and take advantage of the government's 43.5% R&D incentive program. CoSec also works with foreign companies in various industries that wish to establish a presence in the lucrative Australian market. The firm's service package covers market entry assistance, incorporation, and all ongoing accounting, payroll, and tax compliance services necessary to maintain a compliant entity.

"This is the logical next step for CoSec and presents a strategic opportunity to be part of a larger international team with established resources and networks across Acclime's established Asian portfolio," Blair Lucas, Co-founder and Chief Executive Officer of CoSec said. "We are excited at the opportunities that lay ahead and the value we can deliver to Acclime's clients through our presence and deep understanding of the Australian, US and UK markets."

"Each market has its own complex corporate and compliance regimes which are difficult to navigate for companies who are looking to expand into new regions," Paul Dixon, Co-founder and Chief Financial Officer of CoSec said. "As a result of this strategic integration, our clients can benefit from a wider spectrum of professional services and gain access to regional experts to help them navigate complex emerging Asian markets."

"Australia is a trading nation and a high-growth destination for foreign investment. Twelve of its 15 largest markets are in Asia and Oceania, showing how integrated Australia's economy is with the Asian neighbours," Martin Crawford, Co-founder and CEO of Acclime said. "With our expansion plan, having a strong footprint in Australia - an integral and desirable market in the Asia-Pacific region - is critical. CoSec fits perfectly with what we do at Acclime - assisting clients to expand and succeed in whichever Asian market they choose to enter and operate within."

CoSec will formally transition to the Acclime brand on 1 June 2021.

About Acclime

Acclime, the premier corporate services provider in Asia, helps corporate and private clients to advance their businesses and interests in difficult-to-navigate markets in emerging Asia. The company's vision is to reinvent the corporate services sector with innovative solutions that are seamlessly delivered to the highest global standards.

For further information, please visit www.acclime.com

About CoSec

Established in 2011, CoSec has successfully managed the initial and ongoing Australian expansions for over 500 clients across a broad range of industries. Our full capabilities include company incorporation, compliance and accounting support, registered office and CFO services, and resident directors. CoSec is located in Melbourne, Sydney, Brisbane and Adelaide, with representatives based in San Francisco and London.

Logo - https://mma.prnewswire.com/media/971256/Acclime_RGB_Logo.jpg

© 2021 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.